Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)

Basit Öğe Kaydı
dc.contributor.authorStrumberg, Dirk
dc.contributor.authorSchultheis, Beate
dc.contributor.authorEbert, Matthias Philip
dc.contributor.authorKerkhoff, A.
dc.contributor.authorHofheinz, Ralf Dieter
dc.contributor.authorBehringer, Dirk M.
dc.contributor.authorSchmidt, Wolfgang E.
dc.contributor.authorGoker, Erdem
dc.contributor.authorDe Dosso, Sara
dc.contributor.authorKneba, Michael
dc.contributor.authorYalcin, Suayib
dc.contributor.authorOverkamp, Friedrich
dc.contributor.authorSchlegel, Frank
dc.contributor.authorDommach, M.
dc.contributor.authorRohrberg, Robert
dc.contributor.authorSteinmetz, Tilman
dc.contributor.authorReuter, Dirk
dc.contributor.authorBach, Ferdinand
dc.date.accessioned2019-10-27T21:52:11Z
dc.date.available2019-10-27T21:52:11Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2013 -- Chicago, ILen_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15en_US
dc.identifier.urihttps://hdl.handle.net/11454/47528
dc.identifier.volume31en_US
dc.identifier.wosWOS:000335419601384en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePhase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu